*sponsored by TradingTips

GM! As usual here are today’s biggest movers. And right now we have a great special going on for ALL our services. Why choose one when you can have them all? Call Davis for more info (1-800-585-4488 / davis@ragingbull.com).

P.S. Don’t forget to join us in Market Masters to kick the week off right!

FOCUS LIST🔎

RDHL – Up over 40% in the pre-market after announcing positive obesity and Diabetes results with Opaganib

TNXP – Up  over 30% in pre after reporting Q2 financial results and operational highlights

FUBO – Up over 13% in pre after announcing it had won a preliminary Injunction Against The Walt Disney Company, FOX Corp. and Warner Bros. Discovery’s Venu Sports Joint Venture

HOTLIST🔥

RDHL – Up over 40% in the pre-market after announcing positive obesity and Diabetes results with Opaganib

RedHill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company that primarily focuses on gastrointestinal and infectious diseases.

In the pre-market this morning, the company announced positive results from multiple in vivo studies, undertaken by RedHill’s partner, Apogee Biotechnology Corporation, showing the impact of opaganib[2] on weight gain and glucose tolerance in a high fat diet (HFD) model, supporting the potential clinical use of Opaganib for the prevention and therapy of Type 2 diabetes and other obesity-related disorders.

The encouraging outcomes showed the benefit of opaganib therapy in suppression of HFD-induced body weight gain, loss of glucose tolerance and fat deposition. Additionally, opaganib treatment reduced weight gain and restored glucose tolerance in an already obese HFD model, suggesting its potential for treating, not just preventing, obesity-related disorders.

The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034 – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Trulicity (dulaglutide) and Mounjaro (tirzepatide) and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim’s Jardiance (Empagliflozin).

RDHL traded up over 40% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $0.4627.

Beyond that, $0.5440, $0.6134 and $0.80 come into play.

Below $0.4627, targets to the downside are $0.40, $0.35, and then a gap fill at $0.2901. 

TNXP – Up  over 30% in pre after reporting Q2 financial results and operational highlights

Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company that focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.

In the pre-market this morning, the company reported Q2 financial results and operational highlights.

Highlights include:

On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in second quarter 2024

FDA granted Fast Track designation for TNX-102 SL for fibromyalgia

Commercial planning continues for U.S. launch of TNX-102 SL, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia

U.S. Department of Defense contract awarded for up to $34 million over 5 years to develop a broad-spectrum antiviral drug

As of June 30, 2024, Tonix had $4.2 million of cash and cash equivalents, compared to $24.9 million as of December 31, 2023. Net cash used in operations was approximately $30.5 million for the six months ended June 30, 2024, compared to $56.3 million for the same period in 2023.

Subsequent to the quarter ending June 30, 2024, Tonix received net proceeds of approximately $3.5 million in a securities purchase agreement with certain institutional and retail investors, and sold 0.8 million shares of common stock under the ATM Sales Agreement, for net proceeds of approximately $0.4 million.

Net product revenue for the second quarter 2024 was approximately $2.2 million. 

The stock traded up over 30% in the pre-market in reaction to the financial results and operational update.

The $0.50 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $0.55, $0.63, $0.72 and then the pre-market high at $0.75. Beyond that, $0.92, $1.10 and $1.30 come into play.

Below $0.50, targets to the downside are $0.4474, and then $0.42.

FUBO – Up over 13% in pre after announcing it had won a preliminary Injunction Against The Walt Disney Company, FOX Corp. and Warner Bros. Discovery’s Venu Sports Joint Venture

fuboTV Inc. (FUBO) operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally.

Late Friday, the company reported that it has been successful in stopping the launch of The Walt Disney Company, FOX Corp. and Warner Bros. Discovery’s Venu Sports joint venture (JV) after its request for a preliminary injunction was approved by the U.S. District Court, Southern District of New York today.

Today’s ruling is significant as Fubo fought against three of the world’s biggest media conglomerates to create a more competitive streaming marketplace for consumers.

David Gandler, co-founder and CEO, Fubo, commented:

“Today’s ruling is a victory not only for Fubo but also for consumers. This decision will help ensure that consumers have access to a more competitive marketplace with multiple sports streaming options.

“But our fight continues. Fubo has said all along that we seek equal treatment from these media giants, and a level playing field in our industry.

Fubo had sought to stop the launch of the JV that would have controlled roughly 60%-80% of live broadcast sports content, according to its partners.

Fubo presented evidence of the JV’s primary effect of limiting competition, removing consumer choice, and ultimately leading to steep price hikes for consumers and boosting profits for the partners. Fubo’s goal is to ensure a competitive sports streaming marketplace that offers consumers choice, affordable pricing, flexibility and innovation.

All distributors should have the opportunity to compete in a fair market, according to Fubo.

The stock traded up over 13% in the pre-market this morning after closing Friday up over 16%.

The first target for bulls is the pre-market high $1.83.

Beyond that, $2.13, $2.64 and $3.33 come into play.

Below $1.83, targets to the downside are $1.70, $1.63, $1.50, $1.40 and then $1.30.

MARKET NEWS 📰

Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull